DURHAM, N.C.--(BUSINESS WIRE)--Oct. 30, 2018--
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company),
announced today that its third quarter 2018 financial results will be
released after the market closes on Tuesday, November 6, 2018. Following
the release, the Company will host a live conference call and webcast at
5:00 p.m. Eastern Time to discuss the Company’s financial results and
provide a general business update.
The live webcast and a replay may be accessed by visiting the Company's
website at http://investors.aeriepharma.com.
Please connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call (888)
734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live
conference call. The conference ID number for the live call 9894007.
Please dial in approximately 10 minutes prior to the call. Telephone
replay will be available approximately two hours after the call. To
access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406
(international). The conference ID number for the replay is 9894007. The
telephone replay will be available until November 14, 2018.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma, retinal diseases and
other diseases of the eye. Aerie's first product, Rhopressa® (netarsudil
ophthalmic solution) 0.02%, a once-daily eyedrop approved by the U.S.
Food and Drug Administration (FDA) for the reduction of elevated
intraocular pressure (IOP) in patients with open-angle glaucoma or
ocular hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse
reactions were conjunctival hyperemia, cornea verticillata, instillation
site pain, and conjunctival hemorrhage. More information about Rhopressa®,
including the product label, is available at www.rhopressa.com.
Aerie’s advanced-stage product candidate,
Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a
fixed-dose combination of Rhopressa® and the
widely-prescribed PGA (prostaglandin analog) latanoprost, achieved its
3-month primary efficacy endpoint in two Phase 3 registration trials,
Mercury 1 and Mercury 2, and also showed safety and efficacy throughout
12 months in Mercury 1. Aerie submitted the Roclatan™ New Drug
Application (NDA) in May 2018 and, in July 2018, the FDA set the PDUFA
(Prescription Drug User Fee Act) goal date for the completion of the
FDA’s review of the Roclatan™ NDA for March 14, 2019. Aerie continues to
focus on global expansion and the development of additional product
candidates and technologies in ophthalmology, including for wet
age-related macular degeneration and diabetic macular edema. More
information is available at www.aeriepharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005003/en/
Source: Aerie Pharmaceuticals, Inc.
McClellan, Inc., on behalf of Aerie Pharmaceuticals